Angion Biomedica : Current Corporate Presentation

ANGION

Investor Presentation

January 5, 2022

Important Notice

All statements other than statements of historical facts contained in this presentation, including statements regarding Angion Biomedica Corp.'s ("we" or the "Company") strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements about the potential benefits, activity, effectiveness and safety of ANG-3777,ANG-3070 or our product candidates, the success and timing of our pre-clinical studies and clinical trials, including the timing and availability of data from our clinical trials of ANG-3777 and ANG-3070, the primary endpoints to be utilized in our clinical trials, our ability to obtain and maintain regulatory approval of ANG-3777,ANG-3070 and any other product candidates we may develop, and the labeling under any approval we may obtain, the scope, progress, expansion, and costs of developing and commercializing our product candidates, the size and growth of the potential markets for our product candidates and the ability to serve those markets, our expectations regarding our expenses and revenue, the sufficiency of our cash resources, and needs for additional financing, regulatory developments in the United States and other countries, the rate and degree of market acceptance of any future products, the implementation of our business model and strategic plans for our business and product candidates, including additional indications for which we may pursue, our expectations regarding competition, our anticipated growth strategies, the performance of third-party manufacturers, our ability to establish and maintain development partnerships, our expectations regarding federal, state, and foreign regulatory requirements, our ability to obtain and maintain intellectual property protection for our product candidates, the successful development for our sales and marketing capabilities, the hiring and retention of key scientific or management personnel and the anticipated trends and challenges in our business and the market in which we operate.

These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends we believe may affect our business, financial condition, and operating results. These and other risks are described more fully in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 12, 2021, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. You may get these documents for free by visiting EDGAR on the SEC web site at http://www.sec.gov. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Angion undertakes no duty or obligation to update any forward-looking statements containing in this presentation as a result of new information, future events or changes in its expectations.

2

STRATEGIC OBJECTIVES

Develop ANG-3070 in multiple kidney fibrosis indications

Develop ANG-3070 in IPF and other lung fibrosis indications

Complete the full analysis of ANG-3777 clinical data to determine the future of the program

Determine lead compounds and disease area focus for our pre-clinical programs

3

Angion's Development Pipeline

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3		Next Anticipated Milestone(s)
Candidate
Fibrosis
ANG-3070*	Primary Proteinuric Kidney Diseases (FSGS, IgAN)						1H-2023: Phase 2 PPKD data
(Tyrosine Kinase
Inhibitor)	Idiopathic Pulmonary Fibrosis (IPF)						2022: File IND in IPF
ROCK2	Fibrosis						2022: Nominate lead compound and initiate
Inhibitor						IND-enabling studies
Aldosterone Synthase Dysregulation
CYP11B2	Aldosterone-Related Diseases						2022: Nominate lead compound and initiate
Inhibitor						IND-enabling studies
Acute Organ Injury
ANG-3777**	Acute Kidney Injury Associated with Cardiac Surgery						Q1-2022: Determine next steps for program
(HGF mimetic)	Involving Cardiopulmonary Bypass (CSA-AKI)

Partnered with Vifor Pharma

* The Phase 1 study for ANG-3070 was conducted in healthy volunteers and is expected to support Phase 2 trials across indications.	4
** ANG-3777 Phase 2 trial in CSA-AKI and a Phase 3 trial in delayed graft function, a severe form of AKI, both showed no statistical significance on their primary endpoints.

ANG-3070

Potential Best-in-Class Oral Tyrosine Kinase Receptor Inhibitor for Fibrotic Diseases of the Kidney and Lung

5 5